公开(公告)号：US20140242177A1

公开(公告)日：2014-08-28

申请号：US14353118

申请日：2012-10-19

Applicant: Keith SIMONS ,  Estelle SIMONS ,  Ousama RACHID ,  NOVA SOUTHEASTERN UNIVERSITY

Inventor： Mutasem Rawas-Qalaji ,  Keith Simons ,  Estelle Simons ,  Ousama Rachid

IPC: A61K9/14 ,  A61K9/00 ,  A61K47/36 ,  A61K47/02 ,  A61K31/137 ,  A61K31/194

CPC classification number: A61K9/14 ,  A61K9/006 ,  A61K9/2054 ,  A61K9/5115 ,  A61K9/5161 ,  A61K31/137 ,  A61K31/194 ,  A61K47/02 ,  A61K47/36

Abstract: The invention provides compositions including epinephrine nanoparticles and methods for therapeutic use of the compositions in the treatment of conditions responsive to epinephrine such as a cardiac event or an allergic reaction, particularly anaphylaxis. The epinephrine nanoparticles can be incorporated into orally-disintegrating and fast-disintegrating tablet pharmaceutical formulations and can significantly increase the sublingual bioavailability of epinephrine, and thereby reduce the epinephrine dose required. Additionally, the invention provides methods for fabrication of stabilized epinephrine nanoparticles for use in the described compositions.

Abstract translation: 本发明提供了包括肾上腺素纳米颗粒的组合物和用于治疗使用该组合物治疗对肾上腺素如肾脏疾病如心脏事件或过敏反应特别是过敏反应的病症的方法。 肾上腺素纳米颗粒可以掺入到口腔崩解和快速崩解片剂药物制剂中，并且可以显着增加肾上腺素的舌下生物利用度，从而降低所需的肾上腺素剂量。 另外，本发明提供了用于制备用于所述组合物的稳定的肾上腺素纳米颗粒的方法。

公开(公告)号：US20160045457A1

公开(公告)日：2016-02-18

申请号：US14778887

申请日：2014-03-24

Applicant: Ousama RACHID ,  Keith SIMONS ,  Estelle SIMONS ,  NOVA SOUTHEASTERN UNIVERSITY

Inventor： Mutasem RAWAS-QALAJI ,  Ousama RACHID ,  Keith SIMONS ,  Estelle SIMONS

IPC: A61K31/137 ,  A61K9/00

CPC classification number: A61K31/137 ,  A61K9/0056 ,  A61K9/006 ,  A61K9/14 ,  A61K31/00 ,  A61K47/12 ,  A61K47/26

Abstract: The invention provides compositions including epinephrine fine particles, including epinephrine nanoparticles or nanocrystals and epinephrine microparticles or microcrystals, and methods for therapeutic use of the compositions for the treatment of conditions responsive to epinephrine such as a cardiac event or an allergic reaction, particularly anaphylaxis. The epinephrine fine particles can be incorporated into orally-disintegrating and fast-disintegrating tablet pharmaceutical formulations and can significantly increase the sublingual bioavailability of epinephrine, and thereby reduce the epinephrine dose required.

Abstract translation: 本发明提供了包括肾上腺素细颗粒，包括肾上腺素纳米颗粒或纳米晶体和肾上腺素微粒或微晶的组合物，以及用于治疗使用该组合物治疗对肾上腺素（例如心脏事件或过敏反应特别是过敏反应）的病症的方法。 肾上腺素细颗粒可以掺入口腔崩解和快速崩解片剂药物制剂中，并可显着增加肾上腺素的舌下生物利用度，从而降低所需的肾上腺素剂量。

公开(公告)号：US20150164827A1

公开(公告)日：2015-06-18

申请号：US14408038

申请日：2013-06-14

Applicant: Ousama RACHID ,  Keith SIMONS ,  Estelle SIMONS ,  NOVA SOUTHEASTERN UNIVERSITY

Inventor： Mutasem Rawas-Qalaji ,  Ousama Rachid ,  Keith Simons ,  Estelle Simons

IPC: A61K31/137 ,  A61K9/14 ,  A61K9/00

CPC classification number: A61K31/137 ,  A61K9/0056 ,  A61K9/14 ,  A61K9/2054

Abstract: The invention provides compositions including epinephrine nanoparticles and methods for therapeutic use of the compositions for the treatment of conditions responsive to epinephrine such as a cardiac event or an allergic reaction, particularly anaphylaxis. The epinephrine nanoparticles can be incorporated into orally-disintegrating and fast-disintegrating tablet pharmaceutical formulations and can significantly increase the sublingual bioavailability of epinephrine, and thereby reduce the epinephrine dose required. Additionally, the invention provides methods for fabrication of stabilized epinephrine nanoparticles for use in the described compositions.

Abstract translation: 本发明提供包括肾上腺素纳米颗粒的组合物和用于治疗性使用该组合物用于治疗响应于肾上腺素（例如心脏事件或过敏反应，特别是过敏反应）的病症的组合物。 肾上腺素纳米颗粒可以掺入到口腔崩解和快速崩解片剂药物制剂中，并且可以显着增加肾上腺素的舌下生物利用度，从而降低所需的肾上腺素剂量。 另外，本发明提供了用于制备用于所述组合物的稳定的肾上腺素纳米颗粒的方法。

公开(公告)号：US20070202163A1

公开(公告)日：2007-08-30

申请号：US11672503

申请日：2007-02-07

Applicant: Mutasem RAWAS-QALAJI ,  Keith SIMONS ,  Xiaochen GU ,  Estelle SIMONS

Inventor： Mutasem RAWAS-QALAJI ,  Keith SIMONS ,  Xiaochen GU ,  Estelle SIMONS

IPC: A61K31/137 ,  A61K9/20

CPC classification number: A61K9/0056 ,  A61K9/006 ,  A61K9/2009 ,  A61K9/2054 ,  A61K31/137

Abstract: Described herein are formulations for fast-disintegrating epinephrine tablets which can be prepared for buccal or sublingual administration, wherein the fast-disintegrating epinephrine tablets can produce plasma epinephrine concentrations substantially equivalent to those achieved by traditional injectable dosage forms comprising epinephrine injected either subcutaneously or intramuscularly.

Abstract translation: 本文描述了可以制备用于口腔或舌下施用的快速崩解肾上腺素片剂的制剂，其中快速崩解的肾上腺素片剂可以产生与通过皮下或肌内注射的包含肾上腺素的传统可注射剂型形成的血浆肾上腺素浓度基本相同的血浆肾上腺素浓度。

公开(公告)号：US20070059361A1

公开(公告)日：2007-03-15

申请号：US11530360

申请日：2006-09-08

Applicant: Mutasem Rawas-Qalaji ,  Keith Simons ,  Xiaochen Gu ,  Estelle Simons

Inventor： Mutasem Rawas-Qalaji ,  Keith Simons ,  Xiaochen Gu ,  Estelle Simons

IPC: A61K9/20 ,  A61K31/137

CPC classification number: A61K9/006 ,  A61K9/0056 ,  A61K9/2009 ,  A61K9/2054 ,  A61K31/137

Abstract: Described herein are formulations for fast-disintegrating epinephrine tablets which can be prepared for buccal or sublingual administration, wherein the fast-disintegrating epinephrine tablets can produce plasma epinephrine concentrations similar to those achieved by an approximately 0.3 mg epinephrine dose in the thigh (Epi-Pen).

Abstract translation: 本文描述了可以制备用于口腔或舌下给药的快速崩解肾上腺素片剂的制剂，其中快速崩解的肾上腺素片剂可产生与大腿中约0.3mg肾上腺素剂量（Epi-Pen）相似的血浆肾上腺素浓度 ）。